Keywords: EpiCept, Peripheral neuropathy, AmiKet, Ceplene, Azixa, Edison Investment Research

EpiCept moving forward with pain, say Edison analysts

Article | 13 June 2012

Print This

US drug developer EpiCept’s (Nasdaq; EPCT) investment case is centered on finding a development partner for AmiKet (amitriptyline 4%, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in